Cisplatin - A more Efficient Drug in Combination with Radionuclides?

Area of Science:

• Radiochemistry
• Molecular Biology
• Oncology

Background:

• Combination therapy using chemotherapeutics and radionuclides aims to reduce side effects and increase efficacy.
• Investigating the synergistic effects of chemotherapeutic agents and radioisotopes is crucial for optimizing cancer treatment strategies.

Purpose of the Study:

• To investigate DNA damage induction by cisplatin in combination with various radionuclides.
• To determine if platinum atoms influence Auger electron emission and subsequent DNA damage.

Main Methods:

• pUC19 plasmid DNA was incubated with cisplatin and irradiated with 99mTc, 188Re, and 223Ra.
• DNA strand breaks (single- and double-strand) were quantified to assess damage levels.

Main Results:

• Cisplatin's threshold concentration for pUC19 plasmid DNA tolerance was 18-24 nM.
• No significant increase in DNA strand breaks was observed with combined cisplatin and radionuclide treatment compared to radionuclides alone, even at high doses (>100 Gy).

Conclusions:

• DNA strand break induction is not directly dependent on the presence or absence of platinum atoms attached to DNA.
• Observed DNA damage in cellular studies is influenced by study design and cellular repair mechanisms.
• Radioactive cisplatin, incorporating Auger electron emitters like 191Pt, presents a promising future therapy by combining cytostatic and radiopharmaceutical actions for tumor cell killing.